Tests a smaller radiation area for glioblastoma brain tumor patients
Compares two radiation safety margins in adults with glioblastoma brain tumors.
Plain-language title generated from the registry record
Registry title: Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
Key facts
- Where
- Aalst, Baudour, Bruges, Brussels, Genk, Ghent, Gilly, Hasselt, Kortrijk, La Louvière, Leuven, Liège, Mechelen, Montigny-le-Tilleul, Mouscron, Namur, Roeselare, Uccle, Verviers, and Wilrijk, BelgiumSee the 23 sites
Where in Belgium
- Olv AzorgAalst, BelgiumNot yet recruiting
- EpiCURABaudour, BelgiumTaking people
- AZ Sint JanBruges, BelgiumTaking people
- Cliniques universitaires Saint-LucBrussels, BelgiumTaking people
- Institut Jules BordetBrussels, BelgiumNot yet recruiting
- UZ BrusselBrussels, BelgiumNot yet recruiting
- Ziekenhuis Oost-Limburg (ZOL)Genk, BelgiumTaking people
- AZ Sint-LucasGhent, BelgiumTaking people
- UZ GentGhent, BelgiumNot yet recruiting
- Grand Hôpital de CharleroiGilly, BelgiumTaking people
- JESSA ZiekenhuisHasselt, BelgiumTaking people
- AZ GroeningeKortrijk, BelgiumTaking people
- Chu HeloraLa Louvière, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
- CHU LiègeLiège, BelgiumTaking people
- AZ Sint MaartenMechelen, BelgiumTaking people
- Hôpital André Vésale - HUmaniMontigny-le-Tilleul, BelgiumTaking people
- CH MouscronMouscron, BelgiumNot yet recruiting
- CHU UCL Namur - Sainte ElisabethNamur, BelgiumTaking people
- AZ DeltaRoeselare, BelgiumTaking people
- Cliniques de l'EuropeUccle, BelgiumTaking people
- CHR VerviersVerviers, BelgiumTaking people
- ZAS AugustinusWilrijk, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Trial code
- NCT06719440
- Record updated
- 27 February 2026
- Original description
The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life.Read full original descriptionShow less
Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study
The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life.
The glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments.
Radiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the "Clinical Target Volume" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation.
The BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.
Inclusion: Participants capable of giving informed consent; Age >= 18 y.o; WHO performance status 0-2; Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection ); Indication of chemoradiotherapy confirmed by multidisciplinary tumour board.
Exclusion: Participation in a competing trial; Known contraindication to undergo MRI scans.